Q: What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?
At the end of this crisis, we will need to ask ourselves what can be done to better leverage the collective wisdom within the pharmaceutical industry and academia to accelerate the development of life-saving vaccines safely and in quantities needed for global use. Equally important will be the need to address the issue of maintaining a resilient supply chain during such outbreaks to manufacture and transport pharma goods quickly and safely to patients in need. Western countries, knowing that their pharma supply chain for APIs was mostly in Asia, realized that risks could become a reality with such a rare and critical event as the COVID-19 pandemic. Setting up local API supply chains will be a very hot topic to anticipate and to transform into reality with the support of public and pharma authorities.